News
Hosted on MSN24d
JAK inhibitor combo therapy shows promise for myelofibrosis treatment in phase 3 trialMore information: Raajit K. Rampal et al, Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial, Nature Medicine (2025). DOI: 10.1038/s41591-025-03572-3 ...
Investors wanted more from Incyte Corp.’s top-line results in hidradenitis suppurativa (HS) from its pivotal phase III Stop-HS trial program with oral small-molecule JAK1 inhibitor povorcitinib in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results